论文部分内容阅读
目的对尿激酶与静脉溶栓治疗急性心肌梗死后出现的不良反应进行探讨。方法对50例接受静脉尿激酶溶栓治疗患者的临床治疗资料给予回顾性研究分析。结果 50例患者出现不良反应6例,不良反应率为12%。其中急性脑出血4例,过敏皮疹2例,皮下出血症状1例;其中出现脑出血症状患者3例,2例发生在溶栓治疗环节中,还有1例出现在溶栓治疗后的2 h内,此3例患者均已死亡。结论脑出血为急性心肌梗死患者静脉尿激酶溶栓治疗后较为严重的不良反应,一旦患者出现脑出血就会伴随着治疗失败导致患者死亡的后果,因而相关医护人员必须要在治疗过程中时刻观察患者生理指标进而避免患者出现脑出血状况。
Objective To investigate the adverse reactions of urokinase and intravenous thrombolysis after acute myocardial infarction. Methods The clinical data of 50 patients receiving intravenous urokinase thrombolysis were retrospectively analyzed. Results 50 patients showed adverse reactions in 6 cases, the adverse reaction rate was 12%. There were 4 cases of acute intracerebral hemorrhage, 2 cases of allergic rash and 1 case of subcutaneous hemorrhage. Among them, 3 cases showed symptoms of cerebral hemorrhage, 2 cases occurred in thrombolytic therapy, and 1 case appeared in 2 h after thrombolysis All three patients were dead. Conclusions Cerebral hemorrhage is a serious adverse reaction after thrombolytic therapy of intravenous urokinase in patients with acute myocardial infarction. Once the patients have cerebral hemorrhage, they will be accompanied by the consequence of the patient’s death caused by failure of treatment. Therefore, relevant medical staff must observe the time during treatment The patient’s physiological indicators in turn prevent the patient from developing cerebral hemorrhage.